Hello, everyone. Thank you for joining Terumo Corporation's financial results briefing for the fiscal year ended March 2026 out of your busy schedules today. Today's proceeding is the following. First, Mr. Hagimoto, Group Executive Officer and CFO, will provide an overview of the financial results. Nextly, Mr. Samejima, Chief Executive Officer, and Mr. Carsten Schroeder, President of Neuro Business, who is joining online, will make a presentation, GS 2026 final year and beyond, and Terumo Neuro growth roadmap. Finally, we have time set aside for questions and answers. We are planning a total of 60 minutes. This webinar is available both in Japanese and English using Zoom's simultaneous interpretation function. Please use the audio switch button at the bottom of the screen as required.
Please note that the materials shared on the screen will be displayed in the same language as the speaker. Materials in Japanese or English only can be viewed on our website. Should any technical issues arise with the streaming, we will notify you by email. Prior to the start of the briefing, we advise you of the following disclaimer. Today's presentation may include forward-looking statements based on our current projections, which are all subject to risks and uncertainties. Actual results may differ from these projections. We thank you for your understanding in advance. Mr. Hagimoto will explain the financial results summary. Mr. Hagimoto, please go ahead.
I'm Jin Hagimoto, CFO of Terumo. I will walk you through an overview of our financial results for the fiscal year ended March 2026. Let me begin with the key highlights. In FY 2025, revenue reached JPY 1.1 trillion, marking our 5th consecutive year of record high sales. Supported by a favorable business environment, demand expansion in North America led overall growth, resulting in 9% year-on-year growth on a local currency basis. On the profit side, although we recorded the impact of U.S. tariffs and one-time expenses related to acquisitions and business restructuring, we achieved record high profits in line with revenue growth.
For the FY 2026 guidance, we aim to deliver record highs for the sixth consecutive year in revenue operating profit and profit for the year, driven by strong organic growth as well as contributions from OrganOx acquired last year. Please note that as of April this year, the business segment of OrganOx has been named Terumo Organ Technologies. Next slide, please. Moving on to our PL performance. As mentioned earlier, revenue continued to grow globally, led by North America, reaching a record JPY 1.1 trillion for the full year.
Operating profit and adjusted operating profit also reached record highs at JPY 176.3 billion and JPY 219.4 billion, respectively. In the H2, the impact of U.S. tariffs became more pronounced and geopolitical uncertainty in the Middle East persisted. Despite these challenges, we successfully maintained the profit margins at a level comparable to the previous year through pricing measures and cost controls. Looking at Q4 specifically, margins temporarily declined due to tariff impacts and the recognition of one-time expenses. I will explain the details on the next slide. The next slide, please. Here I would like to explain the one-time expenses and adjustment items recorded in FY 2025 as well as our outlook for FY 2026.
As previously disclosed, during fiscal years 2024 and 2025, we conducted ongoing reviews of underperforming businesses and projects to assess whether investments were delivering returns consistent with their original intent. As a result, in FY 2025, we recorded JPY 48.8 billion in one-time expenses, mainly related to new acquisitions and business portfolio optimization alongside recurring amortization from past acquisitions. Additionally, we recognized JPY 5.5 billion in litigation-related expenses in Q4, which were not included in our Q3 assumptions. This relates to a class action lawsuit involving our blood and cell technologies company. They were recorded as one-time expenses to mitigate uncertainty and potential future costs associated with prolonged litigation. This does not represent any admission of legal liability or wrongdoing, nor does it affect our business operations or mid to long-term strategy.
While FY 2025 saw a concentration of acquisition-related and other one-time expenses, we view these as strategic investments for future growth. As a result, we are entering FY 2026 with a much cleaner cost base, which we believe positions us to further accelerate growth. In FY 2026, the absence of these one-time expenses is expected to contribute more than JPY 10 billion to profit growth. Next slide, please. Now I will explain the year-on-year profit variance for Q4. There are two key factors. First, gross margin and pricing. From Q3 onward, tariff impacts became more significant, resulting in a JPY 5 billion negative impact in Q4. Pricing had a positive effect of JPY 3.1 billion. However, impairment losses of JPY 2.2 billion related to the termination of certain projects led to a negative impact of JPY 4.5 billion.
These impairment losses are included under restructuring expenses in the previous slide. Second, R&D expenses increased due to impairment of capitalized R&D assets in Q4. Both factors are temporary and will not have a continuing impact in FY 2026 or beyond. Moving on to the full year profit variance analysis. Overall, continued demand growth and higher sales volumes were the primary drivers of profit growth. The gross profit increment by sales increase was driven mainly by overseas TIS, primarily in North America, as well as Global Blood Solutions led by the plasma business. With regard to the gross margin pricing measures, especially in C&V, contributed positively. However, these gains were offset by the full year impact of tariffs and impairment losses associated with discontinued projects. SG&A increased in line with business expansion and remained broadly within our expectations.
I will now explain performance by company, starting with C&V, the Cardiac and Vascular Company. Revenue increased by 7% on a local currency basis, with strong performance continuing globally, particularly TIS in North America and the neuro business. In North America, all TIS product categories performed well, with volume growth contributing more significantly than pricing. The neuro business continued to deliver strong growth, especially in China and Japan. The profit margin in FY 2025 was 24%. Q4 margin temporarily declined to 19%, mainly due to impairment losses related to a change in development locations for new products in TIS, as well as negative impact from foreign exchange on a stock basis. In FY 2026, we expect margins to improve as these temporary factors subside. Next slide, please. Next is TMCS, the Medical Care Solutions Company. Growth in pharmaceutical solutions drove both revenue and profit growth for the company overall.
This was led by the domestic CDMO business as well as the strong performance of projects overseas. In hospital care solutions, despite the impact of a business transfer in Q1 of the previous year and a supply issue with a certain product, the supply issue has since been resolved and growth in Asia contributed to higher sales. Profit increased due to the effects of pricing measures and disciplined cost control. Although the Leverkusen plant consolidated from Q3 had a negative profit impact of JPY 3.7 billion, it is excluded here to clearly illustrate the performance of existing businesses. Regarding the Leverkusen plant, we continue to see strong interest, particularly from European U.S. pharmaceutical companies, and we are making steady progress toward securing new projects. Next slide, please. Next, TBCT, the Blood and Cell Technologies Company.
Revenue increased, driven by expanded deployment of Reveos, an automated whole blood processing system, as well as growth in plasma innovations with Global Blood Solutions. Global Therapy Innovations also performed well, particularly in North America. Profit increased due to strong core businesses, including Reveos and improved profitability of expanded sales of Rika. In the H2 , we implemented production adjustments related to Rika. However, those remained within our expectations, and the impact on profit margins was limited. In FY 2026 as well, production adjustments may be made depending on circumstances, but at this stage, we expect the impact on business performance to be minimal.
I will explain the performance of Terumo Organ Technologies. Since Q3, we have included this business in our consolidated results. In Q4, revenue was JPY 5.1 billion and adjusted operating profit was JPY 1.1 billion. To illustrate the growth trend, we also disclosed the full year FY 2025 performance on a year-on-year basis. Revenue increased by 48% on a local currency basis. The profit margin reached 21%, reflecting that a high margin business model has already been established. The organ preservation market utilizing NMP is expected to continue expanding, supported by the increase in liver transplant procedures and the expansion of our customer base, we aim to achieve growth exceeding that of the market. Let me move on to revenue by region. In the Americas, demand continued to expand, with all companies delivering strong growth.
TIS, Pharmaceutical Solutions, and Global Blood Solutions were a key driver. In Europe, TIS and Neuro remained stable growth contributors, while Pharmaceutical Solutions grew, supported by strong project sales. In Japan, the CDMO business performed well, contributing to higher Pharmaceutical Solutions revenue. Neuro and C&V continued double-digit growth. In China, growth was driven primarily by Neuro, supported by expanded market access resulting from VBP. In Asia, strong TIS performance led C&V growth, with TBCT also delivering double-digit growth. Next slide, please. Let me explain our FY 2026 guidance. First, I would like to explain the key assumptions underlying our FY 2026 guidance. The first assumption reflects the recent surge in crude oil prices stemming from the situation in the Middle East. Based on the information currently available, we have incorporated the impact of higher raw material and related costs into our guidance.
At this stage, thanks to the cooperation of our suppliers, there have been no issues affecting production or supply. The second assumption concerns U.S. tariffs. We have assumed a tariff rate of 10% through July, and while conditions thereafter remain uncertain, we have incorporated a rate of 15% into our guidance based on our prior circumstances. Under these circumstances, for FY 2026, we expect revenue to grow by 8% on local currency basis. Operating profit is projected to increase by 20% year-over-year, significantly outpacing revenue growth, mainly due to the absence of one-time expenses recorded in the previous fiscal year. FY 2026 marks the final year of our five-year growth strategy, GS 2026. We expect to achieve record high revenue and profits, and we are on track to meet the financial targets set under GS 2026. This slide presents our guidance by company.
We aim to achieve high single-digit revenue growth across all companies by steadily expanding high margin growth drivers in each company while advancing operational improvements in the introduction of new products. We expect profit growth to exceed revenue growth in all cases. The inclusion of Terumo Organ Technologies is expected to become one of the key drivers of overall group growth. Alongside its strong revenue growth, we expect profits of JPY 5.1 billion, making this business a contributor in terms of both growth potential and profitability. This slide explains the year-on-year profit variance in FY 2026 guidance. The GP increment by sales increase is the primary factor behind profit growth, reflecting continued growth across businesses such as TIS and Neuro, as well as the full year contribution from Terumo Organ Technologies.
With regard to the gross margin, we expect a negative impact of JPY 4.5 billion due to the impact of tariffs throughout the year. Higher raw material costs are expected to have a negative impact of JPY 2.5 billion. We expect a positive impact of JPY 10 billion from pricing measures, as well as JPY 7.5 billion from the absence of one-time expenses recorded in the previous fiscal year and cost reduction effects associated with business restructuring. SG&A are expected to increase at a healthy level in line with business expansion. Next slide, please. This slide outlines our product expected to drive further growth as well as our key regional expansion initiatives. From FY 2026 onward, we will continue to create growth opportunities by allocating resources to growth areas and expanding sales of new products.
In C&V, we will continue to focus on growth segments with large market opportunities in the therapeutic area to drive business expansion. In the access area, we will promote the adoption of radial procedures, and together with the expansion of the therapeutic area, aim for further growth. In TMCS, we will further advance the creation of new value by leveraging devices, pharmaceuticals, and digital solutions, and expand the provision of a wide range of solutions, including medical management. We aim to expand the CDMO and project businesses while accelerating overseas expansion by matching our strength with region-specific needs. In TBCT, the rollout of Reveos is accelerating, and we will continue to expand into new regions. By expanding software and service offerings, including the use of AI and enhancing infrastructure through automation, we will secure competitive advantages and achieve further customer acquisition. Next slide, please.
Finally, let me touch on shareholder returns. For FY 2025, we expect an annual dividend of JPY 30 per share with a payout ratio of 33%. For FY 2026, we plan to increase the dividend by JPY 6, bringing it to JPY 36 per share with a payout ratio of 32%. We continue to prioritize growth investments while we remain committed to stable and progressive dividend increases going forward. This concludes my presentation. Thank you very much for your attention.
Next, CEO Samejima and President Schroeder will present. President Samejima, please go ahead.
I am Hikaru Samejima, CEO of Terumo Corporation. Thank you very much for coming. I would like to share our perspective on the final year of GS 2026 and our strategic direction beyond that. We will explain the strengths and future outlook of Terumo Neuro, which continues to drive strong growth for C&V as well as the company overall. Let me begin with our progress this fiscal year toward the key financial targets of GS 2026. Regarding the revenue growth, GS 2026 defined a target range of high single-digit growth. This year as well, driven primarily by organic growth, we are steadily expanding the top line as planned and expect revenue growth to come in within our target range.
As for the operating profit, through continued progress in pricing measures and optimization of our cost structure, we expect to reach a level of 20% or more in FY 2026. In addition, while continuing to invest for growth, we plan to maintain ROIC at a level of 10% or higher. This demonstrates that we are steadily achieving both profitability and capital efficiency. In this way, in FY 2026, the final year of GS 2026, we expect to reach the target ranges initially set for all three key financial indicators, revenue growth, operating profit, and ROIC. Next, I will outline the key growth drivers supporting our performance this fiscal year.
Let me start with C&V. Business fundamentals remain strong, particularly in the endovascular segment. Along with continued pricing measures, mainly in North America, core products such as Ultimaster Nagomi and WEB are expected to drive revenue growth this year. Turning to TMCS, the global CDMO business continues to expand with new product launches. Project-centered products are the main growth drivers, while ongoing pricing measures are improving profitability of TMCS as well. As for TBCT, revenue growth driven by the plasma business continues, and core products such as Reveos provide stable support.
Finally, Terumo Organ Technologies. As NMP adoption expands and the liver transplant market grows, we are gaining market share through metra. As shown, this year's performance is supported by steady, plan-based growth across multiple businesses, underpinning our ability to achieve the GS 2026 financial targets. With that, I will now hand over to Carsten Schroeder, President of Terumo Neuro, who will outline the strong growth outlook for Terumo Neuro this fiscal year.
Thank you, Hikaru. I'm Carsten Schroeder, President and CEO of Terumo Neuro. I will walk you through today the growth of Terumo Neuro to date, our key strengths and successes, and our strategy for the future. The neurovascular business provides endovascular treatment solutions for both ischemic stroke, which is a blocked artery, and hemorrhagic stroke, which is a leaking artery in the brain. Terumo entered this space first through the acquisition of MicroVention, initially focused on coil-based therapies for hemorrhagic stroke. Since then, the business has expanded organically into a full-scale, class-leading neurovascular portfolio addressing both ischemic and hemorrhagic stroke. Following this, the acquisition of Sequent Medical added the intrasaccular WEB embolization device, creating a new treatment category where we continue to hold global leadership.
The business has consistently delivered above-market, double-digit growth driven by leadership in key platforms, including the WEB intrasaccular device for hemorrhagic stroke and SOFIA catheters for ischemic stroke. Our core strength lies in our ability to continuously innovate, expand, and iterate our product portfolio while building robust clinical evidence to support long-term adoption. Combined with strong commercial and operational capabilities, this allows us to successfully deliver our solutions on a global basis. Under the Terumo Neuro brand, we are focused on sustaining category leadership in core therapies while selectively expanding into adjacent markets to deliver on our vision to restore brain health globally. A hemorrhagic stroke is fundamentally a leak or weakening in the blood artery in the brain, leading to a bubble or aneurysm.
The portfolio to treat this disease state could involve placing a stent in the artery or filling the aneurysm with numerous coils or putting a single device like the one pictured on the left, which is called the WEB intrasaccular device. The ischemic stroke on the right is a blockage in the artery that can be removed with a stent retriever or by suctioning out through an aspiration catheter or both. To get to the brain from either the groin in the leg or the wrists, you can deliver therapies and devices, and that requires catheters and guide wires under therapeutic lesion access. The neurovascular business has grown to become complete and class-leading since the acquisition of MicroVention in 2006, with coils as the foundation for the portfolio.
Growth has been driven primarily by organic innovation, complemented by the acquisition of Sequent Medical in 2016, which created a new category of intrasaccular devices. In 2024, MicroVention was rebranded as Terumo Neuro, reflecting our ambition to further expand the business and advance our vision to preserve and restore brain health. Terumo Neuro has consistently delivered double-digit and above-market revenue growth. This consistent growth has been achieved with market-leading brands such as WEB for hemorrhagic and SOFIA for ischemic stroke, sustained leadership in therapy lesion access, and continued overall portfolio expansion. We finished fiscal year 2025 with $710 million in sales, primarily coming from therapeutics. Here are the highlights of the growth strategy of Terumo Neuro. We will continue to deliver above-market growth through three strategic pillars.
We plan to grow its current business by introducing new products in hemorrhagic and ischemic and generate clinical evidence. The second pillar, we plan to expand production capacity and improve gross margins. Beyond these two, the growth drivers of the existing core business, we will expand into adjacent markets using our core portfolio and clinical capabilities to drive new indications and commercial expansion. One of our key strengths lies in our ability to integrate technologies and continuously iterate on them over time. While some companies also offer both coils and intrasaccular devices, Terumo Neuro's differentiation lies in how deeply and consistently we integrate and evolve these technologies over multiple generations. By combining our core expertise with the WEB platform, we have established a new standard of care in specific aneurysm segments and achieved strong number one positions.
Since the acquisition of Sequent Medical, we have successfully advanced WEB from generations 1 to the current generation 6, supported by accumulated clinical evidence and procedural expertise, with generations 7 already in the pipeline. This long-term, disciplined approach to technology integration is what enables Terumo Neuro to deliver sustainable above-market growth. Another key strength of Terumo Neuro is our leadership in clinical evidence generation and neurovascular devices. We are conducting large-scale post-approval studies across key products with global patient enrollment underway in the United States, Europe, Japan, China, and beyond. Taking comprehensive long-term approach, we have built a broad body of clinical data across geographies, studies, publications, and device platforms. This depth of evidence supports regulatory approval and market access while strengthening physician confidence and establishing our technologies as standard of care.
The intrasaccular market created by Terumo Neuro is growing at an annual rate of over 10%. Terumo Neuro established this market with a WEB embolization device, a first-in-class technology refined over more than 15 years with over tens of thousands of patients treated globally. Looking ahead, we aim to maintain category leadership in intrasaccular therapy through continued product development. We will also expand clinical indications, including ruptured aneurysm in North America and Asia, while further strengthening clinical evidence generation through global studies. Terumo Neuro is also known for its class-leading SOFIA catheter brand in ischemic stroke treatment. Aspiration catheters today are used in 90% of the cases, with six French-sized catheters being the majority used. A new category of larger-sized catheters called Superbore has recently emerged.
Terumo Neuro has category leadership in the six French aspiration catheter market with the SOFIA Flow, with extensive clinical literature supporting its use. We plan to further develop its leadership in the emerging Superbore category with the introduction of the SOFIA 88. Terumo Neuro has a significant portion of its manufacturing operations in Costa Rica, benefiting from strong government support, an attractive talent pool, and a well-developed ecosystem around medical device technology. We aim to execute our long-term manufacturing strategy by improving cost of goods sold through increased automation, leveraging capabilities from the Terumo Interventional Systems business. In parallel, we are expanding production capacity for key products while maintaining the high quality of our product offerings. We also see attractive growth opportunities as we expand into adjacent neurovascular markets. The neurovascular market continues to grow at around 6% annually.
At the same time, new treatment areas, such as chronic subdural hematoma, are emerging, attracting increasing clinical interest and innovation. We approach these opportunities with deliberate focus. Rather than broader expansion, we selectively develop offerings where our existing technologies and clinical expertise can be most effectively leveraged. Chronic subdural hematoma is a clear example of how expanding clinical indications allow us to expand our portfolio and capture incremental growth while maintaining strategic discipline. This summarizes our view on the future of Terumo Neuro. Our ambition is to further drive growth in the neurovascular business while contributing to company-wide growth by developing class-leading and commercially scalable solution in our core therapies. Our pipeline includes both iterative improvement in intracerebral devices and new product offerings, supported by continued expansion of clinical evidence.
At the same time, we are improving operational efficiency to ensure these innovations can be scaled effectively and selectively expanding into adjacent markets through indication expansion. Through this focused and disciplined approach, Terumo Neuro aims to preserve and restore brain health while delivering sustainable long-term growth. It has been a pleasure to speak with you today, and I look forward to the Q&A session. Thank you.
Finally, I would like to share our direction towards GS 20 31, which we plan to announce this December. Through GS 20 26, Terumo has built a solid foundation in revenue growth, profitability, and ROIC. Under GS 20 31, building on this foundation, we intend to go beyond simply expanding sales or growing profits by further accelerating innovation. We aim to create new value for patients. Looking ahead, the needs of patients and healthcare professionals will continue to become more advanced and more diverse. Leveraging our strength in technological innovation, clinically driven product development, and global business execution, Terumo will continue to pursue value creation that enhances the quality of healthcare itself. Through these efforts, we aim to achieve sustainable revenue growth and profit expansion while becoming a global top-tier med tech company.
Beyond FY 2026, Terumo will continue striving for even higher levels of growth and performance, transforming the future of healthcare with innovation as our core driving force. Thank you very much for your attention.
We will now move on to the Q&A session. This meeting is a hybrid meeting. For those of you in the room, please raise your hand if you have any questions. For those of you joining remotely, please press the Raise Hand button. If you want to cancel, please press the Raise Hand button again. Please limit your questions to two, so that we can take questions from many of you. The Q&A session will be joined by Samejima, Schroeder, Hagimoto, Otaka, Head of the Management and Administration Division. We would like to open the floor for questions. From Mizuho, we would like to take a question from Kotani-san.
Hello, I am from Mizuho. My first question is related to cost on page 16 for next year. Gross margin is + JPY 4.1 billion, raw material cost is also going up. Transportation cost is also going up as well. How come this is positive? I just cannot understand why, because it's so far off from my assumption. Could you please explain? I think this has to do with Rika and TransMedics. If possible, please share numbers.
Thank you very much for your question. As was explained earlier, this year we have one-time expenses in the U.S. for production. That is included in this year, JPY 2.5 billion, this will go away. Also restructuring cost and overseas plant restructuring expenses will actually be positive this fiscal year. Gross margin is based on those factors. One-time expenses will disappear this fiscal year. Understood.
Next question, I would like to ask in English if possible.
Yes. There's three questions rolled into one. Let me talk about the intrasaccular segment first. As you saw on the slide earlier, we are on generation 7 with our WEB device, and we continue to have new sizes. We continue to have a small delivery system with a 7 French system. We continue to expand our clinical indications and roll out on a global basis. We already have competition in certain geographies, and we believe that we can maintain a leading market share through continued iteration of this device and continued expansion of the clinical indications around the key markets in the world. As far as aspiration catheter is concerned, you are right. The 88 large bore segment is primarily driven by U.S.-based companies.
We have our distal access catheter, the SOFIA 88. We will be conducting the necessary work to get to an aspiration indication and to create the SOFIA Flow. Flow is our name for the SOFIA catheter, which has an aspiration indication, which is particular to the U.S. market. We are also working on additional sizes and lengths for the SOFIA catheter portfolio. Again, it's a question of iteration in completing our leading portfolio over time. Chronic subdural hematoma is indeed a new phenomenon, essentially by embolizing the MMA. You need two things to do it. You need a catheter, and you need a liquid embolic.
We have a leading catheter with our Headway DUO, which is the most used catheter in this particular segment, we are leveraging the strength of the catheter over into the liquid embolic. We will be investing money also to do a necessary clinical trial for in United States. You're welcome.
Next, we have a question from Yoshihara-san from UBS.
This is Yoshihara from UBS Securities. C&V. If we look at C&V only and the actual track record and the plan, especially profit margin is going to improve significantly, that is your assumption. Therefore, maybe 24 will become 27, 3 point improve. This is adjusted operating margin. One-off expenses and organic, what are your expectations? The lending result, I think the lending result was slightly less than the company forecast, but can this all be explained by one-off factors? Thank you very much for your explanation.
C&V profit margin. 2 point or so from this year to next fiscal year, there will be an improvement. That is because, as I mentioned earlier, in Americas, there was cancellation of production project, 1 point is one-off factor involved. In overseas plants, there are reduction in force in C&V. This fiscal year, this is going to be positive, which means more than JPY 2 billion positive in this fiscal year. Finally, foreign exchange. This fiscal year, the stock impact of foreign exchange in cardio and vascular, there was some impact which will improve profit margin next fiscal year. Especially TIS North America and Terumo Neuro, where profitability is high, they will be growing a lot and contributing significantly as well. That is also a factor.
Thank you very much. Just to make sure, I want to confirm that is FX stock, JPY 4.7 billion company-wide. C&V only, how much?
Mostly all coming from C&V.
I see. Then my second question to you is Rika business. As Hagimoto explained at the beginning, there is going to be a risk of adjustment, I understood In CSL's financial results, supply and demand being not good, we hear, and CSL in itself seems to be losing share from competition or losing share to competition. How is this factored in into this fiscal year's plan? There can be some adjustment, but will not affect profit, you said. Why? What is the logic?
For us, the CSL sales and for Rika, this is almost all the sales of Rika. As of now, from CSL, we are receiving orders, and looking at the orders from CSL now, the order level is within what we expected. There can be some ups and downs in the order level that we experienced in the past years, but that impact to the total of TBCT is going to be very small, we expect. With CSL, we are confirming circumstances on ongoing basis as necessary, as a result, what we thought would affect our results are all affected and all factored in into our expectation.
Moving on, Mori-san of Nomura Securities, please.
This is Mori from Nomura Securities. My first question is slide 15. Leverkusen plant. Included and without Leverkusen plant, you have the disclosure. If we ex Leverkusen, then the Leverkusen impact is going to be bigger than the last fiscal year. Why is Leverkusen impact is going to be greater, and when will this situation start improving? Can you explain further about Leverkusen?
This is about Leverkusen. This fiscal year, we are booking costs for six months. No, correction, that is last fiscal year. Last fiscal year, cost for Leverkusen was booked last fiscal year. This fiscal year will be booked for the full year. Finally, Leverkusen investments will reach a full-fledged stage. That is the background. Here, while plant to injection, you are going to convert the plant into, how much have you progressed, have you received clearance? From multiple pharma companies, we have signed NDAs. We will conduct promotions and development going forward. We are moving ahead. If I may add, clean room construction is progressing as planned.
I see. Thank you. My second question is about OrganOx. Currently, crude prices are high and inflation is ongoing, which means organ transplant costs must be going up. As operating profit margin, can you maintain 20%? You expect to maintain 20% because the top line will not affect profit margin. What is going to be the impact on profitability to OrganOx coming from inflation and higher crude prices?
Japanese plants and Asian plants will be impacted a lot from crude. For OrganOx business, we do not expect big impact. With sales increasing, as you said, profit is going to expand. This is the structure of the business. If I may add, the transportation itself is not included in our business model. The transportation part can be mostly be ignored. People in transportation can pass on cost suppressing, but you are a machine business. You don't receive as much cost pressure. You are not receiving cost pressure that much. More than 90% of the businesses in U.S. In U.S., the Middle East circumstance is not as much impactful compared to the Far East or Japan.
Thank you. Moving on to Citigroup. Yamaguchi-san, please.
Can you hear me now? I have just unmuted.
Yes.
I have two brief questions. The first is, in the next midterm plan, the growth, the CAGR, I think you said is going to go up, there are more business segments now. When you aim for the next midterm period, you will achieve this growth level, then is there going to be further growth after the near-term result?
We want to aim for higher goals compared to the current GS 2026. Upon this direction, we want to get into December.
I see. The raw material cost increase impact is going to be JPY 2.5 billion. What is the impact coming from the Middle East? Are there any comments?
Inside the slide, the JPY 2.5 billion is raw material cost increase that is coming from the Middle East. Middle East circumstances resulting in raw material cost increases in this fiscal year's earnings forecast. As you are very well aware, tariff impact.
Tariff, maybe you can get the tariff paid back to you. Maybe you can get payment returns?
Yes. There are many uncertainties as of this point. Therefore, as of this point, still there is the 10% tariff applied at the end, up to the end of July. This is the assumption, up to the end of July. So far used to be 15%, there is still a possibility the tariff may go back up to 15%. Repayment back of tariff, there are such movements emerging, we are aware, in the U.S. There is still time available for appeal, but we have not factored this possibility in our forecast.
Thank you. SMBC Nikko Securities, Tokumoto San, please.
This is Tokumoto from Nikko Securities. I have two questions for you. The first is guidance, TMCS. Leverkusen, excluding Leverkusen, you are going to increase a lot of profits. This profit margin improvement and profit increase between CDMO versus Japanese existing business, can you give me the split? What is going to be the profit margin improvement between CDMO and existing Japanese business? Can you give me the breakdown?
Thank you very much for pointing out. Last fiscal year, FY 2025, in fentanyl there were out of stocks. This year, this is going to recover. In addition, in MCS, Japan and global, there will be price pass-ons, pass-throughs taking place this fiscal year. In addition, CDMO business is going to expand. These are the factors and contributors for profit margin improvement in FY 2026, which means in the whole of TMCS, there will be improvements.
Yes. Secondly, I want to ask about neuro strategy. First of all, brain aneurysm in the next five years, as there was also a question earlier. The competition will start catching up in the next five-year time period. Amongst this background, how are you going to innovate? What are the innovations are you going to come up with? There can be more flow diverters and mesh, and there can be more improvements. Stryker is also catching up with similar innovations. Brain aneurysm versus Stryker, what is your strategy? Also the aspiration, brain stroke may be may be more vulnerable compared to stent. Having stent and retriever, having the combination business, you may not have this in your pipeline. I would like to hear about your big strategy.
Please wait until the translation is finished.
Thank you very much for the question. Let me talk about hemorrhagic stroke first. You have multiple ways to treat aneurysms, ruptured or unruptured. You have coils, you have flow diverters, you have intrasaccular devices, you have stent-assisted coiling. Terumo Neuro has the most complete portfolio. We are the only company with coils who has class 1A evidence of randomized clinical trials with our HydroCoils. We are the market leader in intrasaccular, and we are also very strong in stent-assisted coiling and flow diverters. We have a pipeline and projects to continue to iterate on all four categories. That is for hemorrhagic stroke.
As far as ischemic stroke is concerned, SOFIA is the class leader in this in this segment, and we are expanding the segment also by adding new sizes to this portfolio over the next couple of years. We do have a combination in each of the major geographies, Europe, United States, China and Japan. We also have a stentriever available, and we offer the combination technique of stentriever plus aspiration catheter.
Thank you very much. I have a related question. Flow diverter, I think FRED has strong pipeline. In China, Chinese companies, including MicroPort, they are selling their version of the products. However, application expansion is still under preparation. When you think about the next five years for aneurysm and for stroke, how big do you think that the Chinese companies will be in the future? How big of a threat are they going to be?
We should not underestimate the Chinese companies. There are a lot of Chinese companies now in China, in neurovascular, as they are in peripheral or in cardiology. Obviously, they would like to expand internationally, meaning moving out of China. Some of these Chinese companies also have highly differentiated products. I would not only see them as a competitive threat, I would also seize them as a source of new products, new product innovation.
Understood. Thank you very much.
We have received some comments from you. Competition is becoming more intensified for Neuro, Terumo Neuro. Competitive advantage and improving its competitiveness is something that we need to think about, and tuck in type M&A is something that we might consider in the future.
Next, we have Tony Ren from Macquarie Capital.
Hi, Tony Ren from Macquarie. Thank you for taking my questions. I have two as well. The first one is I would like to ask you about the TMCS, particularly the pharmaceutical solutions. On page 9, you said in Japan, the CDMO business did very well. Could you help me understand what proportion that comes from LEQEMBI, Eisai's LEQEMBI? Recently, there is a delay of FDA's approval of the LEQEMBI auto-injector in induction therapy. Would like to get some sense how does that affect your Japan CDMO business. That's my first one. My second question is again going back to Rika.
It, I think as the other analyst mentioned, we are really seeing a very unusual situation of oversupply. In my experience, this type of oversupply lasts a few years. Would like to see how you have incorporated that into your near-term or mid-term plan. Possibly it will be something in the growth strategy 2031, but just wanted to see whether you have incorporated that into your medium-term planning, probably at least five years. Yeah. Thank you. Okay. Thank you very much. Very good. I'll be looking forward to GS 2031. Thank you.
Next, from Morgan Stanley, MUFG Securities, Hayashi-san, please go ahead.
Hello, I am Hayashi from Morgan Stanley. Can you hear me?
Yes, we can.
I have one question. Maybe it was already covered earlier. This fiscal year, FY 2026, your sales plan, if you exclude Forex, growth rate is also disclosed by segment. Terumo Medical Care Solutions is 8% growth for sales. This company, I think in the past, was only able to grow by mid-single digit or low single-digit percentage. This time around, you're expecting 8% growth. What's different now? Could you please share with us your thoughts? Which business is growing? I guess it's CDMO, but please confirm whether my thinking is correct. 8% growth is relatively high. Could you please tell us why?
Yes. There are three factors. First of all, in FY 2025, there was a shortage. Second is global pricing passthrough, and that will be added onto the sales value and pharmaceutical business. We are receiving orders from pharma companies, and they will promote sales growth.
That means that these are contents you have covered from the past?
We are receiving many more hands up, but this is now time to finish. This is time to finish the meeting. We will close the questions and answers session. For the questions we were not able to take today, please contact our IR department individually. With this, we conclude Terumo Corporation's financial results presentation for the year ending March 2026. Thank you very much for your participation.